60 results about "Secondary disease" patented technology

Novel, advantageous oral compositions formulated to affect any one or combination of the following: reduce physical and mental fatigue, enhance activity, improve recovery from activity, promote muscle performance, increase energy substrates, contribute to improved antioxidant defenses (i.e., reduce oxidative stress or lipid peroxidation, conserve anti-oxidants in the sera), enhance mood, assist in preventing primary and secondary diseases associated with fatigue and muscle atrophy associated with inactivity, improve nervous system (i.e., neuronal) and musculoskeletal (i.e., increase skeletal muscle protein synthesis, increase satellite cells) health, and contribute to improvements in overall health. The compositions of the subject invention are preferably used as a replacement for a snack or meal in cases of hunger or fatigue for individuals across the broad spectrum of human function from elite athletes to those individuals compromised by aging and certain disease states.

The present invention relates to 2′-Fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Hepatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and / or adefovir resistant) and other mutant forms of these viruses.

The present invention relates to 2′-Fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and / or adefovir resistant) and other mutant forms of these viruses.

The present invention relates to the discovery of an epigenetic relay pathway that controls hepatic stellate cell activation and the wound-healing response in fibrogenesis, including fibrogenesis of the injured liver. Methods of inhibiting fibrogenesis, including liver fibrogenesis and secondary disease states and conditions thereof, and in treating liver damage, including cirrhosis of the liver (which may be caused by viruses or chemicals, including alcohol), are aspects of the present invention. The methods utilize certain nucleoside compounds and / or antibodies which are optionally conjugated. Pharmaceutical compositions represent additional aspects of the invention.

The present invention relates to 2′-Fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and / or adefovir resistant) and other mutant forms of these viruses.

The present invention relates to novel N-sulfamoyl-piperidineamides of Formula I and their physiologically acceptable acid addition salts, to pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment of obesity and its concomitant and / or secondary diseases and related or other conditions.

The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and / or prevention of an array of the manifestations of metabolic syndromes, including Type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat, inhibit or reduce the likelihood of hepatitis viral infections, including Hepatitis B and Hepatitis C viral infections, as well as the secondary disease states and / or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, among other disease states or conditions.

The present invention generally concerns the management of age-related diseases in domestic animals. Specifically, the present invention is directed to combination therapies for the treatment of progressive renal diseases (e.g., Chronic Renal Failure) and their accompanying secondary disease states. In a composition aspect, the present invention provides a composition comprising a phosphate binder and another pharmaceutically active ingredient. The other pharmaceutically active ingredient is selected from a group consisting of antihypertensives, calcitrol, vitamin D analogues, lipid restriction products, potassium salts, treatments for anemia and alkalization compounds.

The invention provides a compound and application of the compound and the pharmaceutically acceptable salt thereof or a stereo isomer or a prodrug molecule thereof in preparing a medicament for treating or preventing metabolic diseases, wherein the compound has the structural characteristic of a general expression I and is used as a novel fat cell type fatty acid binding protein FABP inhibitor. The compound having the structural characteristic of the general expression I can provide a new selection for the clinical prevention and treatment of the following diseases: 1. type II diabetes, 2. hyperglycemia, 3. hypoglycemia tolerance, 4. insulin resistance, 5. adiposity, 6. lipid turbulence, 7. blood-lipoid imbalance, 8. hyperlipaemia, 9. hypertriglyceridemia, 10. hypercholesterolemia, 11. low high-density protein level, 12. overhigh low-density protein level, 13. atherosclerosis and secondary diseases thereof, 14. hemadostenosis, 15. abdominal obesity, 16. a metabolic syndrome and 17. fatty liver.

The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and / or prevention of an array of the manifestations of metabolic syndromes, including Type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat, inhibit or reduce the likelihood of hepatitis viral infections, including Hepatitis B and Hepatitis C viral infections, as well as the secondary disease states and / or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, among other disease states or conditions.

A bisflavone medicine for preventing and treating gout, preventing the xanthine and hypoxanthine from being oxidized to become uric acid, and relaxing the hyperuricemia and its secondary diseases is prepared from one or more of bisflavone compounds and the auxiliaries.

The invention discloses a degerming agent for crops. The degerming agent comprises the following components in parts by weight: 4 to 8 parts of dandelion, 3 to 7 parts of garlics, 2 to 9 parts of ephedra, 5 to 8 parts of berberisthunbergiicv atropurpurea, 1 to 5 parts of rhizoma atractylodis, 8 to 11 parts of wikstroemia dolichantha, 3 to 9 parts of radix sophorae flavescentis, 9 to 13 parts of angled bittersweet, 5 to 9 parts of lithospermum, 2 to 10 parts of fructus cnidii, 8 to 11 parts of gallnut, 4 to 9 parts of eucommia ulmoides, 3 to 6 parts of erose mussaenda leaves, 8 to 13 parts of melia azedarach, 7 to 11 parts of pokeberry roots, 2 to 6 parts of wild chrysanthemum flowers, 5 to 10 parts of rhododendron molle and 7 to 14 parts of radix scutellariae. In the mode, the degerming agent for the crops has excellent effects on treatment on multiple diseases, the effects can be quickly achieved, the crops can normally recover to produce fast, and the secondary disease development is prevented; the degerming agent has few residues on the crops, and harms cannot be caused even if people eat the degerming agent.

The present invention relates to the discovery of an epigenetic relay pathway that controls hepatic stellate cell activation and the wound-healing response in fibrogenesis, including fibrogenesis of the injured liver. Methods of inhibiting fibrogenesis, including liver fibrogenesis and secondary disease states and conditions thereof, and in treating liver damage, including cirrhosis of the liver (which may be caused by viruses or chemicals, including alcohol), are aspects of the present invention. The methods utilize certain nucleoside compounds and / or antibodies which are optionally conjugated. Pharmaceutical compositions represent additional aspects of the invention.

The invention relates to a road engineering detection technology, and particularly relates to a pavement crack development state detection method based on a ground penetrating radar and coring. The method comprises the following steps of 1, detecting a crack to obtain a crack ground penetrating radar image; 2, performing analysis processing on the obtained ground penetrating radar image, thereby determining the type and the position of the crack; 3, carrying out drilling-for-core on the crack to obtain a core sample of a road section; and 4, carrying out measurement and observation on the obtained core sample to obtain a development state of the crack and a state of a base layer at the crack. By using the method disclosed by the invention, the road crack and the crack ''secondary disease''can be found in time, and the complete development state of the crack can be accurately detected, so that a scientific maintenance scheme can be adopted, and the situation that the pavement crack control is not timely and good can be effectively avoided; and therefore, the method has great significance for delaying heavy repair and prolonging the road service life.

The present invention relates to 2′-Fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and / or adefovir resistant) and other mutant forms of these viruses, especially HBV.

The invention discloses a preparation method of nanoscale calcium hydroxide, and relates to the technical field of adhesive for preservation of cultural relics. The method comprises the following steps: (1) mixing: mixing calcium hydroxide with alcohol solvents so as to form mixed liquid; (2) dispersing: adding an anti-agglomeration auxiliary agent into the mixed liquid, and then dispersing to form a dispersed material; (3) grinding: adding a grinding auxiliary agent into the dispersed material, and then grinding to form ground material; (4) filtering: filtering the ground material, and then obtaining a product. The calcium hydroxide adhesive prepared by the method does not contain moisture, is especially suitable for repairing limestone and mural painting cultural relics, and does not cause secondary diseases and irreversible damage; furthermore, the calcium hydroxide is good in dispersity and small in particle size, so that the calcium hydroxide adhesive is good in permeability during use; the preparation method is simple and is not complicated.

The invention discloses a traditional Chinese application medicament for treating hypertension; the components of the traditional Chinese application medicament comprise 12g of peach kernel, 12g of almond, 3g of gardenia iasminoides ellis, 7 grains of peppers, and 14 grains of sticky rice. The medicaments are mashed and egg albumen of one egg is added and mixed with the medicaments into paste. The obtained medicament can be applied for three times to the plantar estavel acupuncture point before sleep every night, and removed at daytime. Application is performed once every day and to one foot each time with two feet in turn, and six times of application is one course of treatment. Compared with the prior art, the traditional Chinese application medicament has the advantages of both principal and secondary disease aspect treatments, excellent effects, and no side effects.

The invention discloses a biological environment-friendly technique for rearing breeding boar. The biological environment-friendly technique for rearing breeding boar comprises the techniques of building pigsties, setting fermentation beds, proportioning bedding materials, performing daily management, and the like. As the rearing technique sets soft bedding materials in the fermentation beds, breeding boar can thoroughly turn over the bedding materials every day, so that the movement modes and intensity of the breeding boar are increased on the one hand, and manual work for maintaining the bedding materials is saved on the other hand. Meanwhile, biological fermentation bedding materials play a role in adsorbing and transforming toxic and harmful substances, thereby significantly improving rearing environment, allowing pigsties to no longer have ammonia odor of dung / urine, dispelling the special foul odor of the breeding boar, obviously improving air quality and reducing respiratory diseases and secondary diseases.

An airbag type automatic protection device for concrete panel rock-fill dam panel disengagement is arranged in an extrusion side wall under a concrete panel rock-fill dam panel. The automatic protection device is characterized in that the automatic protection device is composed of a protection airbag, an air generator and an automatic triggering device; the protection airbag is installed on the portion, close to the dam crest part, in a precast concrete extrusion side wall; the air generator is connected with the protection airbag through a breather pipe; the automatic triggering device is internally provided with a disengagement quantity detector electric ignition mechanism, and the electric ignition mechanism is connected with the air generator and controls starting of the air generator. According to the airbag type automatic protection device, the blank in the prior art is filled up, when disengagement occurs between the panel and cushion materials and the disengagement amount reaches the quantity value harming the concrete panel safety, the airbag type protection device is automatically started, the inflatable airbag supports the panel, the stress state of the concrete panel is improved, and secondary diseases such as surface cracks, slab staggering and the like are prevented.

The present invention relates to porphyrin analogues, their use in pharmaceutical compositions alone, or combination with other agents and in the treatment and / or prophylaxis of flaviviridae viral infections, especially hepatitis C viral infection, and secondary disease states and / or conditions associated with same.

An object of the present invention is to provide a pharmaceutical agent or composition useful as a muscle-strengthening drug, an anti-inflammatory drug, an antiasthmatic, an antidiarrheal, an antidepressant, or a drug for the treatment of secondary diseases following cerebral infarction, motor paralysis, diminution of vision, hepatitis, inflammatory intestinal syndrome, functional enteropathy, functional cardiopathy, functional hepatopathy, functional nephropathy, dementia, climacteric symptoms, senile dementia and / or Alzheimer disease, and a dermatological agent or composition suitable for skin applications, which can treat or prevent muscle weakening and inflammation, in particular arthritis, by its muscle-strengthening and / or anti-inflammatory actions, said agent or composition comprising isoflavone and / or isoflavone glycoside in combination with a pungent substance, a bitter substance or a sour substance, and cholic acid, and / or scymnol and / or a scymnol ester. The present invention relates to an agent or composition usuful as a muscle-strengthening drug, an anti-inflammatory drug, an antiasthmatic, an antidiarrheal, an antidepressant, or a drug for the treatment of secondary diseases following cerebral infarction, motor paralysis, diminution of vision, hepatitis, inflammatory intestinal syndrome, functional enteropathy, functional cardiopathy, functional hepatopathy, functional nephropathy, dementia, climacteric symptoms, senile dementia and / or Alzheimer disease, and / or an agent or composition to be applied to the skin, said agent or composition comprising isoflavone and / or isoflavone glycoside in combination with a pungent substance, a bitter substance or a sour substance, and cholic acid, and / or scymnol and / or a scymnol ester.

The present invention relates to 2′-Fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Hepatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and / or adefovir resistant) and other mutant forms of these viruses, especially HBV.

Provided is an infant nutrition comprising at least one protease inhibitor, a process for preparing such an infant nutrition and use of the infant nutrition for the treatment and / or prevention of childhood obesity and secondary disorders resulting from childhood obesity.

The invention relates to a Chinese medicinal pill for treating cancer, which is prepared from house lizard, ganoderma lucidum, paris rhizome, cow-bezoar, root of American ginseng and raw licorice root.

The invention belongs to the field of modern traditional Chinese medicine production, and relates to Chinese herbal medicine herba leonuri extract leonurine and application of the leonurine in preparing drugs, in particular to application of the leonurine in preparing a euglycemic agent and preventing the obesity. Through the pharmacological study and insulin sensibilization experiments, the results show that the leonurine has the effect of improving the sensibility of insulin in the body, and the leonurine can enhance the reaction of the body to the insulin, enhance the physiological effect of the insulin and increasing the sensibility of an insulin receptor; the experimental results show that under the condition that the leonurine is far lower than the toxic dose, the effect of reducingthe body weight is shown. The leonurine can be used for preparing the euglycemic agent and the drugs for preventing the obesity and is especially suitable for etiological treatment of the insulin resistance syndrome and the secondary disease symptoms caused by reduction of insulin resistance or insulin sensitivity, such as the central obesity, the simple obesity and the obesity with any other disease states.

The invention discloses an enhanced far infrared antibacterial low-temperature thermoplastic material and a preparation method thereof. The enhanced far infrared antibacterial low-temperature thermoplastic material is prepared from the following raw materials in parts by weight: 60 to 80 parts of polycaprolactone, 20 to 30 parts of nanometer far infrared ceramic powder, 10 to 20 parts of modified glass fiber, 5 to 15 parts of a nano-silver antibacterial agent, 20 to 40 parts of modified talcum powder and 8 to 16 parts of diffusion oil. The preparation method of the modified glass fiber comprises the following steps: firstly soaking and washing the glass fiber with a boric acid solution, then putting the soaked glass fiber into an ammonium persulfate solution for soaking so as to moisten the surface, finally adding into a coupling agent for ultrasonic oscillation, and drying to obtain the material. According to the far infrared antibacterial low-temperature thermoplastic material disclosed by the invention, the strength of the material is greatly improved by adding the modified glass fiber, and the material is expected to be developed into a medical fixing material with plasticity and strength. Moreover, the nanometer far infrared ceramic powder added into the low-temperature thermoplastic material can promote blood circulation and shorten curing time; the added nano-silver antibacterial agent can effectively prevent propagation of bacteria, so that the occurrence of secondary diseases is prevented.

The invention relates to the use of whey permeate, preferably sweet whey permeate and more preferably hydrolysed or partially-hydrolysed sweet whey permeate for the production of a pharmaceutical composition for prophylaxis or treatment of symptoms of metabolic syndrome, type-2 diabetes and secondary diseases, said composition being provided for a mammal.

Novel and known trifluoroacetyl-substituted phenyl, phenol and benzoyl compounds for the treatment and / or inhibition of obesity and of concomitant and / or secondary diseases involved therewith, in particular metabolic syndrome and cardiovascular diseases. Novel trifluoroacetyl-substituted phenyl, phenol and benzoyl compounds, pharmaceutical preparations containing them and processes for the preparation of these compounds. Also compounds acting as inhibitors of lipase, in particular pancreatic lipase.